Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients

Objective:To determine pharmacokinetics (PK), safety and tolerability of a double-chain recombinant human factor VIII-Fc fusion protein (FRSW107) in previously treated patients (PTPs) in clinical trial which was registered at www.clinicaltrials.gov as NCT03747653 and scheduled to finish at end of Ju...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 134; no. Supplement_1; p. 4932
Main Authors Xue, Feng, Sun, Jing, Chen, Yun, Zhang, Xinsheng, Sun, Haiyan, Wang, Yali, Yang, Renchi
Format Journal Article
LanguageEnglish
Published Elsevier Inc 13.11.2019
Online AccessGet full text

Cover

Loading…